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Serotonin-receptorAlzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinergic failure, but other
neuro-transmitters are also deﬁcient especially at late stages of the disease. Misfolded β-amyloid peptide has
been identiﬁed as a causative agent, however inﬂammatory changes also play a pivotal role. Even though the
most prominent pathology is seen in the cognitive functions, speciﬁc abnormalities of the central nervous system
(CNS) are also reﬂected in the periphery, particularly in the immune responses of the body. The aim of this study
was to characterize the dopaminergic and serotonergic systems in AD, which are also markedly disrupted along
with the hallmark acetyl-choline dysfunction. Peripheral blood mono-nuclear cells (PBMCs) from demented pa-
tients were judged against comparison groups including individuals with late-onset depression (LOD), as well as
non-demented and non-depressed subjects. Cellular sub-populations were evaluated by mono-clonal antibodies
against various cell surface receptors: CD4/CD8 (T-lymphocytes), CD19 (B-lymphocytes), CD14 (monocytes), and
CD56 (natural-killer (NK)-cells). The expressions of dopamine D3 and D4, as well as serotonin 5-HT1A, 5-HT2A,
5-HT2B and 5-HT2C were also assessed. There were no signiﬁcant differences among the study groups with re-
spect to the frequencyof the cellular sub-types, however a uniqueprofound increase in 5-HT2C receptor exclusively
in NK-cells was observed in AD. The disease-speciﬁc expression of 5-HT2C, as well as the NK-cell cyto-toxicity, has
been linked with cognitive derangement in dementia. These changes not only corroborate the existence of bi-
directional communication between the immune system and the CNS, but also elucidate the role of inﬂammatory
activity in AD pathology, and may serve as potential biomarkers for less invasive and early diagnostic purposes as
well.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.zeged, Kossuth Lajos sgt. 23, Hungary. Tel.: +36 30 255 6225.
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Alzheimer's disease (AD) is a neuro-degenerative disorder rep-
resenting the most prevalent cause of dementia in the elderly
people world-wide (Alzheimer's Association, 2011). The main
histo-pathological characteristics comprise extra-cellular deposits
of β-amyloid peptide (βAP) forming senile plaques, and neuro-
ﬁbrillary tangles (NFTs) consistingmainly of abnormally phosphorylat-
ed tau-protein within affected brain cells (Hardy and Selkoe, 2002).
These features have been associated with the progressive degeneration
of cholinergic neurons of the basal forebrain and the loss of acetyl-
choline transmission in the hippocampus and cerebral cortex (Bartus
et al., 1982), leading to progressive impairment of cognitive functions,
especially memory. Behavioral changes are also frequent in AD, causing
caregiver stress and increased health expenses (Alzheimer's Association,
2011). These behavioral and psychological symptoms of dementia
(BPSD) include a heterogeneous group of non-cognitive changes
such as apathy, depression, anxiety and delusions (Hersch and Falzgraf,
2007). The cholinergic system plays a fundamental role not only in the
cognitive derangement, but also in BPSD (Cummings and Back, 1998).
The cholinergic hypothesis, however, is not sufﬁcient per se to explain
all symptoms observed in AD (Garcia-Alloza et al., 2005), therefore
other neuro-transmitters are also thought to be involved (Chen et al.,
2011a, 2011b).
Even though technically all transmitter-systems can be altered to
some extent during the course of the disease, mainly in late stages,
dopamine and serotonin have been strongly correlated with cognitive
dysfunctions (Parnetti et al., 2001) and BPSD (Garcia-Alloza et al., 2005;
Proitsi et al., 2012). The availability of dopamine D2-receptors (D2R) is
directly associated with cognitive performance (Kemppainen et al.,
2003), however different alterations in the dopaminergic system may
result in distinct symptoms. The number of D2R is generally reduced
in the hippocampus and amygdala in AD patients (Joyce et al., 1993),
but their abundance is also decreased in the caudate nucleus and puta-
men in AD with Parkinsonism (but not in Parkinson's disease alone)
(Joyce et al., 1998). In contrast, increased D2R availability is seen in AD
with delusions only (Reeves et al., 2009). It has also been hypothesized
that an imbalance between the glutamatergic and dopaminergic sys-
tems may result in psychotic symptoms (Martorana et al., 2010).
Impaired serotonergic homeostasis has also been implicated in BPSD,
causing depressedmood, anxiety, agitation, restlessness and aggressive-
ness (Lanari et al., 2006). Serotonin transmission in general is known to
be decreased in AD (Cross et al., 1988), especially in ﬁbers running from
the rostral raphe nuclei to the temporal lobe (Yamamoto and Hirano,
1985). There are 7 distinct families of serotonin (5-hydroxy-tryptamine,
5-HT) receptors, and various sub-populations have been identiﬁed
(Pytliak et al., 2011) which have distinct localization both in the
central nervous system (CNS) and in the periphery, including in
leukocytes. Peripheral bloodmono-nuclear cells (PBMCs) express sever-
al neuro-transmitter receptors, such as 5-HT, which have been suggested
to reﬂect the status of homologous receptors in the brain (Barbanti et al.,
2000). Immune cells, therefore, have not only been proposed as a model
for studying CNS alterations and for investigating possible systemic
changes in several neuro-psychiatric disorders based on their receptorial
status, but they also play a role in the development of AD. Activated
microglial cells and reactive astrocytes are intimately found in and around
senile plaques, which along with the appearance of inﬂammatory
markers indicate a state of unique endogenous chronic inﬂamma-
tion in AD caused by βAP deposits (Tan et al., 1999; Dumery
et al., 2001; Selkoe 2001). Characteristic functional changes in cellular
blood (including lymphocytes) are being extensively studied, and the
inﬂammatory hypothesis of AD has recently been garnering great inter-
est (Teixeira et al., 2008).
As dopamine and serotonin are involved in the patho-physiology of
AD, and inﬂammatory reaction plays a signiﬁcant role in the disease
mechanism, previous studies have aimed at assessing the neuro-transmitter status of PBMCs in dementia. Reduced D2R and unchanged
D1-receptor density was reported in AD lymphocytes, which correlates
with similar ﬁndings in the brain (Barbanti et al. 2000), however little
information is available on other sub-types. The aim of this study, there-
fore, was to evaluate the expression of various neuro-transmitter recep-
tors in PBMCs in order to gather further indirect information on the
central dopaminergic and serotoninergic function during dementia,
and to develop a reliable and relatively accessible peripheral marker
in AD.
2. Methods
2.1. Subjects
This project evaluated 16 elderly patients with clinically probable AD
according to the National Institute of Neurological and Communicative
Disorders and Stroke, and the Alzheimer's Disease and Related Disorders
Association (NINCDS–ADRDA)work-group criteria. Because of the similar
signs and sometimes over-lapping neuro-psychological symptoms de-
pression may pose a differential diagnostic challenge, 10 patients with
late onset depression (LOD) as conﬁrmed by the 4th edition of the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-IV) criteria have
participated in the study as a comparison group (neuro-psychiatric dis-
ease controls). In addition, 8 non-demented and non-depressed age-
matched individuals were also used as healthy controls based on their
former medical history, somatic and neuro-psychiatric examination.
All subjects were outpatients of the Jenny Faria Center for the Care of
the Elderly and the Women, Universidade Federal de Minas Gerais
(UFMG) in Belo Horizonte, Brazil.
All participantswere thoroughly evaluated, had no infectious process-
es, cancer, inﬂammatory or auto-immune diseases, and hadnot taken any
antibiotics, anti-inﬂammatory, or immuno-suppressive drugs for at least
6 weeks prior to the study. All individuals, or their relatives when appro-
priate, provided written informed consent before admission to the study.
The protocol was approved by UFMG's Research Ethics Committee.
2.2. Samples
Whole blood samples were obtained by veni-puncture using vacuum
tubes containing heparin (Greiner Bio-One International: Kremsmünster,
Austria). In order to rule out any artifacts caused by circadian rhythm,
samples were collected at the same time of the day (between 8:00 and
11:00 am), were kept at room temperature and used within 2 h of
being drawn. In an effort to minimize day-to-day variation that might
occur when performing cell phenol-typing by ﬂow cytometry, at least 1
representative sample from each of the 3 experimental groups were col-
lected and processed each day.
2.3. Study design
2.3.1. Separation of PBMCs
Fresh blood samples were diluted in phosphate-buffered saline
(PBS 1:1), gently layered on Ficoll solution (Ficoll-PaquePlus, GE
Healthcare Bio-Sciences: Uppsala, Sweden) at room temperature,
and centrifuged at 405×g for 40 min. The PBMC-containing layer
was collected and washed twice in PBS at 4 °C. The viable cells, as
determined by trypan-blue exclusion, were re-suspended at the
concentration of 1×107 cells/mL in a medium composed of RPMI-
1640 (Roswell Park Memorial Institute-1640) with L-glutamine
(Sigma-Aldrich: Ayrshire, UK), 40 IU/mL of penicillin, 40 mg/mL of
streptomycin, supplemented with 10% of heat-inactivated fetal bo-
vine serum (Invitrogen: Auckland, New Zealand). PBMCs were then
transferred to a U-bottom 96-well cell culture cluster (Sarstedt:
Nümbrecht, Germany) and maintained in incubator at 37 °C at 5%
CO2 for 14 h.
Fig. 1. Illustrative dot-plot from CytoSoft-GuavaExpressPro v5.3. A: sub-populations of PBMCs. Cells were acquired in cyto-meter and separated by size (forward scatter, y-axis) and
internal complexity (side scatter, x-axis). B: frequency of NK-cells expressing 5-HT2C. PBMCs were stained with anti-CD56 (green ﬂuorescence, x-axis) and anti-5-HT2C (yellow
ﬂuorescence, y-axis). CD56+-cells (NK-cells) are located on the right side of the graph, whereas CD56−-cells (non-NK-cells) are on the left side. PBMCs in the right-lower quadrant
are positive for both CD56 and 5-HT2C (i.e. 5-HT2C over-expressing NK-cells).
Table 1
Socio-demographic characteristics of the participants.
Controls LOD AD P
(n=8) (n=10) (n=16)
Age 81.5±3.70 76.1±7.78 79.2±6.35 0.1a
Sex (female) 62% 60% 66% 0.1b
Education (years) 3.4±2.7 2.7±1.95 4.3±3.01 0.4⁎
MMSE (max. 30) 26.9±1.81 19.8±6.7 13.1±3.94 0.0001⁎
LOD: late onset depression.
AD: Alzheimer's disease.
MMSE: mini-mental state examination.
a One-way ANOVA with Bonferroni post-test.
b χ2-test with Yate's correction.
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PBMCs (2×107) were centrifuged at 330×g for 40 min and the su-
pernatant was discarded. Extra-cellular staining was performed using
mono-clonal anti-bodies labeled with chromophores such as ﬂuorescein
iso-thio-cyanate (FITC), phyco-erythrin (PE), and cychrome-5 (CY5), or
biotin.
Cellular sub-populations were identiﬁed by incubating PBMCs in anti-
CD4-FITC, anti-CD14-FITC, anti-CD56-FITC, anti-CD19-CY5 and anti-CD8-
biot (BD Pharmingen: Franklin Lakes, NJ, USA) for 20 min at 4 °C, then
washed with 0.1% sodium-azide in PBS and ﬁxed with 2% formaldehyde
in PBS. Cells labeled with biotinylated anti-bodies (anti-CD8) were incu-
bated with streptavidin-CY5 solution for 15 min at 4 °C to enable binding
of CY5-labeled streptavidin to biotin.
The primarymono-clonal anti-bodies used for the detection of dopa-
mine (anti-D3, anti-D4) (SantaCruz Biotechnology: Santa Cruz, CA, USA)
and serotonin (anti-5-HT1A, anti-5-HT2A, anti-5-HT2B and anti-5-HT2C)
(Santa Cruz Biotechnology: Santa Cruz, CA, USA) receptors were labeled
with PE (BD Pharmingen: Franklin Lakes, NJ, USA). After staining with
primary anti-bodies, PBMCs were washed with PBS, incubated with sec-
ondary anti-bodies conjugatedwithﬂuoro-phore Alexa-568 (Invitrogen:
Eugene, OR, USA) for 15 min at 4 °C, washed with PBS, ﬁxed with 2%
formaldehyde in PBS for 30 min at room temperature, centrifuged and
re-suspended in PBS for acquisition.
FITC and PE-labeled immune-globulin isotype control antibodies
were included in all experiments. The stained cells were acquired using
Guava-cytometer (GE Technologies: Hayward, CA, USA).
2.3.3. Data analysis and statistical evaluation
Leukocytes were analyzed for their frequencies of surface mark-
er expression using the program CitoSoft-GuavaExpressPro v5.3 (GE
Technologies: Hayward, CA, USA). The frequency of positive cells
was analyzed in two gates for each staining: lymphocyte gate and
monocyte gate. Limits for the quadrant marker were always set
based on negative populations, isotype and secondary antibody
controls. Illustrative dot-plots used in the analysis are depicted in
Fig. 1.
Data of cellular sub-types and receptor-expression are presented as
frequency (%) and median with range. The Shapiro–Wilk test was usedto verify normality: as the data were not normally distributed, sta-
tistical analysis was performed using Kruskal–Wallis test. With re-
spect to socio-demographic data, values are given as arithmetic
mean±standard deviation (SD) or frequency (%) and range. Anal-
ysis of variance (ANOVA) with post-test was used to compare the
mediums of the continuous variables. Evaluation of categorical data
was performed byχ2-test with Yates's correction. All data were analyzed
with SPSS program version 16.0 (IBM Corporation: Somers, NY, USA) as
well as GraphPad Prism version 4.0 for Windows (GraphPad Software
Inc: LaJolla, CA, USA). The level of signiﬁcance was set at Pb0.05 for all
analyses.3. Results
The characteristics of the study populations are described in
Table 1. There was no difference between the groups regarding age,
sex or years of education. AD patients had the worst cognitive perfor-
mance as conﬁrmed by the mini-mental state examination (MMSE),
which is an indicative of their dementia. MMSE of LODs was higher
than in AD, but lower than that seen with control subjects. Even
though this conﬁrms a degree of cognitive impairment in LOD
(Wilkins et al., 2009), however it is not sufﬁcient enough for these
Table 2
PBMC proﬁle delineating the frequency of various cell-types in each sample group.
Cell-type Controls LOD AD Pa
Frequency (%) Median (range) Frequency (%) Median (range) Frequency (%) Median (range)
CD4 29.2 24.7 (19.5–48.2) 32.86 34.7 (15.1–47.1) 30.1 28.1 (11.0–48.6) 0.08
CD8 26.0 26.2 (18–39.5) 31.36 33.8 (13.4–46.4) 30.4 29.0 (14.6–52.0) 0.22
B-cell 10.5 11.0 (1.2–17.4) 8.81 9.3 (1.5–14.2) 7.5 6.6 (1.3–18.3) 0.63
NK 18.7 18.8 (12.8–25.5) 22.96 19.0 (11.3–38.7) 25.2 23.1 (11.3–41.5) 0.41
Mono 84.2 89.6 (59.6–91.8) 82.32 82.9 (57.4–95.0) 80.3 85.1 (69.2–91.7) 0.64
LOD: late onset depression.
AD: Alzheimer's disease.
CD4: CD4+ T-lymphocyte.
CD8: CD8+ T-lymphocyte.
NK: natural-killer cell.
Mono: monocyte.
a Kruskal–Wallis test.
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is above the cut-off level (MMSE: 18) established for their scholastic
attainment (Bertolucci et al., 1994).Table 3
Expression of dopamine- and serotonin-receptors in different cell-types.
Cell-type Controls LOD
Frequency
(%)
Median
(range)
Frequency
(%)
a: Dopamine-receptor, D3-subtype
CD4 0.39 0.26 (0.12–0.93) 0.52
CD8 1.85 1.95 (0.62–3.32) 1.23
B-cell 2.24 1.47 (1.07–4.17) 1.78
NK 0.97 0.75 (0.27–1.84) 1.30
Mono 0.73 0.62 (0.25–1.66) 1.41
b: Dopamine-receptor, D4-subtype
CD4 0.74 0.65 (0.17–1.76) 0.55
CD8 1.97 1.44 (0.99–4.06) 1.89
B-cell 3.17 2.55 (0.18–6.17) 1.97
NK 1.32 1.07 (0.67–2.36) 1.44
Mono 1.75 0.87 (0.54–4.56) 0.91
c: Serotonin-receptor, 5-HT1A-subtype
CD4 0.68 0.53 (0.20–1.48) 0.42
CD8 3.14 2.91 (0.43–6.15) 1.29
B-cell 3.47 2.46 (0.88–9.15) 2.33
NK 1.02 0.63 (0.16–3.10) 1.42
Mono 2.29 1.11 (0.71–6.22) 1.39
d: Serotonin-receptor, 5-HT2A-subtype
CD4 0.77 0.61 (0.41–1.61) 0.48
CD8 1.85 1.84 (0.49–4.25) 1.37
B-cell 3.21 3.42 (0.90–6.25) 2.01
NK 2.29 1.22 (0.55–6.44) 1.67
Mono 1.84 1.16 (0.38–7.05) 2.74
e: Serotonin-receptor, 5-HT2B-subtype
CD4 0.67 0.66 (0.09–1.38) 0.54
CD8 1.99 1.29 (0.36–5.15) 1.03
B-cell 2.37 2.01 (0.09–4.19) 1.81
NK 0.82 0.47 (0.20–3.09) 0.70
Mono 1.27 1.27 (0.48–2.02) 1.10
f: Serotonin-receptor, 5-HT2C-subtype
CD4 0.69 0.64 (0.27–1.22) 0.65
CD8 2.00 1.10 (0.36–5.28) 1.18
B-cell 3.73 3.08 (0.22–9.14) 1.38
NK 0.98 0.75 (0.18–2.49) 1.01
Mono 1.53 1.33 (0.32–2.65) 1.27
LOD: late onset depression.
AD: Alzheimer's disease.
CD4: CD4+ T-lymphocyte.
CD8: CD8+ T-lymphocyte.
NK: natural-killer cell.
Mono: monocyte.
a Kruskal–Wallis test.When evaluating the PBMC proﬁle, there was no statistically
signiﬁcant difference among the frequency of T-lymphocytes
(CD4+ or CD8+), B-lymphocytes (CD19+), monocytes (CD14+)AD Pa
Median
(range)
Frequency
(%)
Median
(range)
0.42 (0.12–1.18) 0.58 0.57 (0.17–1.06) 0.22
0.87 (0.41–0.29) 0.83 0.77 (0.29–2.14) 0.05
1.76 (0.55–3.45) 3.33 3.35 (0.51–8.54) 0.35
1.11 (0.62–2.79) 1.11 0.73 (0.24–2.60) 0.42
1.06 (0.18–3.32) 1.94 1.80 (0.44–4.49) 0.16
0.43 (0.33–1.04) 0.47 0.43 (0.09–1.29) 0.46
1.34 (0.17–5.03) 1.30 1.06 (0.46–2.68) 0.38
1.76 (0.84–3.69) 2.90 1.86 (0.64–8.37) 0.72
1.37 (0.37–2.57) 1.84 0.98 (0.58–2.16) 0.70
0.66 (0.41–2.21) 1.14 0.84 (0.48–2.49) 0.49
0.32 (0.09–0.95) 0.52 0.42 (0.11–1.43) 0.47
1.11 (0.55–3.38) 2.30 1.61 (0.55–7.74) 0.18
2.09 (0.57–6.67) 2.83 1.66 (0.81–8.54) 0.49
1.47 (0.26–3.35) 2.60 1.23 (0.25–8.55) 0.30
1.11 (0.51–3.51) 1.87 1.28 (0.46–5.09) 0.72
0.49 (0.12–0.85) 0.69 0.44 (0.09–2.52) 0.23
1.20 (0.83–2.75) 0.94 0.84 (0.34–2.76) 0.18
1.74 (0.38–4.99) 2.79 2.09 (0.29–5.80) 0.89
1.09 (0.48–4.31) 1.49 0.96 (0.42–5.04) 0.31
1.31 (0.27–7.14) 2.13 1.36 (0.46–8.94) 0.89
0.38 (0.03–1.50) 0.47 0.26 (0.04–2.24) 0.32
0.44 (0,19–4.44) 1.16 0.55 (0.08–9.70) 0.41
1.03 (0.18–5.56) 2.37 1.64 (0.38–5.79) 0.58
0.49 (0.19–1.78) 0.72 0.55 (0.31–1.71) 0.92
0.72 (0.18–2.88) 1.12 0.70 (0.30–2.93) 0.51
0.58 (0.30–1.11) 0.81 0.54 (0.08–4.59) 0.83
1.08 (0.60–1.82) 1.60 1.41 (0.40–4.09) 0.20
1.33 (0.58–2.43) 2.04 1.35 (0.43–4.41) 0.14
0.77 (0.47–2.35) 1.70 1.73 (0.67–2.60) 0.02
1.02 (0.38–3.21) 2.16 1.43 (0.55–5.04) 0.34
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(Table 2).
The study groups demonstrated similar dopamine D3- and D4-
receptor expressions in all cell types (Table 3). The abundance of
5-HT2C receptors in NK-cells was markedly higher in AD patients when
compared to controls or LODs (P=0.02, Fig. 2), however the rest of the
serotonin-receptors (5-HT1A, 5-HT2A, and 5-HT2B) showed no statistical
difference in any cells of any participant (Table 3). The ﬁnding remained
signiﬁcant after stratiﬁcation for all variables.
BPSDwas present in 25% of AD patients. The dopaminergic and sero-
tonergic receptor-proﬁle in the BPSD+ sub-group was similar to that
seen in the whole AD group.
4. Discussion
The probable diagnosis of AD is based on clinical manifestations and
is only conﬁrmed during autopsy following a microscopic examination
of the brain (Dubois et al., 2007). There is an urgent unmet need for an
objectivemethod to support a deﬁnite ante-mortemdiagnosis. Cerebral
biopsy is not possible for obvious reasons, but AD is known to be a sys-
temic disease with the most prominent changes in the memory func-
tions. Therefore, interest has been focusing on peripheral tissues
including lymphocytes (Nagai et al., 1996; Giorelli et al., 2005;Fig. 2. Frequency of leukocytes expressing 5-HT2C in all study groups. PBMCs were kept in cult
(CD8+ T-lymphocytes), anti-CD19 (B-lymphocytes), anti-CD56 (NK-cells), anti-CD14 (monoc
A: CD4+-cells, B: CD8+-lymphocytes, C: B-cells, D: NK-cells and E: monocytes expressing 5
(*Pb0.05, nAD=16, nLOD=5, ncontrols=8).Rodrigues et al., 2005; Kumar and Patel 2007; Reale et al., 2008;
Torres et al., 2009). Indeed, as PBMCs are known to reﬂect changes
in the CNS, peripheral immune cells have been widely used to monitor
cerebral pathologies, including AD (Dolman, 1984; Idoate-Gastearena
and Vega-Vázquez, 1997; Connolly, 1998; Etcheberrigaray et al., 1998;
Andrews and Neises, 2012). An appropriate marker (or set of markers),
therefore, will not only help early diagnosis in AD, but might also be
used to evaluate progression and response to treatment. Studies have
so far failed to identify such biomarkers that would be both selective
and speciﬁc for AD.
Even though acetyl-choline deﬁciency is the primary neuro-chemical
alteration, other neuro-transmitters are also affected in AD. Dysfunction-
al dopaminergic and serotoninergic systems arewell characterized in the
CNS, but peripheral changes are still under extensive research. It is
known that PBMCs express neuro-transmitter receptors and might re-
ﬂect characteristic changes of the diseased brain. A radio-ligand binding
assay study has reported low density of dopamine D2-like receptors on
AD lymphocytes (Barbanti et al., 2000), however their expression is
also known to be altered in schizophrenia (Vogel et al., 2004; Boneberg
et al., 2006) and depression (Rocca et al., 2002), including bipolar disor-
der (Vogel et al., 2004). Another study showed that 5-HT2A changes in
AD platelets are similar to that seen in vascular dementia and in the nor-
mal aging brain (Spigset et al., 2000).ure medium for ~14 h. Cells were labeled with anti-CD4 (CD4+ T-lymphocytes), anti-CD8
ytes) and anti-5-HT2C anti-bodies, and were analyzed with ﬂow cytometry. Frequency of
-HT2C serotonin receptor. Statistical calculations were made using Kruskal–Wallis test
78 L.C.A. Martins et al. / Journal of Neuroimmunology 251 (2012) 73–79This current report has investigated dopamine and serotonin receptor
expressions of PBMCs in AD. No differences were found among the study
groups, except for 5-HT2C receptor whichwas increased in NK-cells of AD
patients (Table 3). Because dopaminergic and mainly serotonergic sys-
tems are known to be altered in several other neuro-psychiatric disorders
as well, especially in depression, LOD subjects were also evaluated in this
study. There was no receptorial change in any cells derived from LOD,
suggesting that the over-expression of 5-HT2C inNK-cells is speciﬁc in AD.
Increased 5-HT2C abundance can reﬂect decreased serotonin-levels,
and might be a compensatory mechanism following reduced serotonin
availability. Low serotonin levels are known to explain symptoms of
BPSD, especially depressedmood, anxiety, agitation, restlessness and ag-
gressiveness (Lanari et al., 2006). Interestingly, although affective disor-
ders are typically also related to serotonin dysfunctions, LOD patients
demonstrated no 5-HT2C changes. It is pertinent to mention that the al-
tered 5-HT2C status of NK-cells in this studywas detected independently
from the presence or absence of BPSD in the participants. Consequently,
the observed ﬁnding may serve as a candidate biomarker in AD, but fur-
ther studies are warranted in this regard.
The disrupted expression of 5-HT2C was observed exclusively in
NK-cells. More than a mere neuro-chemical deﬁcit, this demonstrates
an altered inﬂammatory system in AD with notable implications.
Apart from T-lymphocytes, NK-cells are one of the main producers of
immune-stimulatory interferon-γ (INF-γ) which has the ability to
directly inhibit viral replication. NK-cells, therefore, are important effec-
tors of the innate immune response against viral infections (Trinchieri,
1989). Functional abnormalities of NK-cells in dementia are also
well characterized and known to play some role in the neuro-
inﬂammation seen in AD (Araga et al., 1990, 1991; Solerte et al., 2000;
Masera et al., 2002). Serotonin is recognized to inhibit NK-cell-
induced cyto-toxicity in a dose-dependent manner through 5-HT2C
(Garssadi et al., 1993, Oláh et al., 2005). An over-expression of 5-HT2C,
therefore, leads to decreased NK-activity which could explain earlier
associations between AD and viral (especially cerebral) infections
(Corder et al., 1998; Martin et al., 2011; Sy et al., 2011), conﬁrming the
theory that the development of ADmight be triggered by viral inﬂamma-
tion (Esiri 1982; Miklóssy 2011). In contrast, NK-cell-derived INF-γ
activates indole-amine-2,3-dioxygenase, the enzyme that degrades
serotonin precursor tryptophan (Maes et al., 2011). As such, activation
of NK-cells may lead to decreased serotonin levels which in turn might
cause over-expression of 5-HT2C in NK-cells. Such a compensatorymech-
anism following reduced serotonin availability, however, would also
trigger changes in other serotonin-receptors and in other sub-
populations of PBMCs, not only 5-HT2C in NK-cells. Moreover, studies on
blood and CSF levels, as well as genotype analyses, have failed to demon-
strate anydifferences of INF-γ in AD (Engelborghs et al., 1999; Fehér et al.,
2010; Llano et al., in press). Taken together, the current ﬁnding of 5-HT2C
inNK-cells is not attributable to cytokine response or other compensatory
mechanisms, but truly reﬂect an AD-speciﬁc change.
Limitations of this study include the small sample size, and the fact
that participants used medications that could not be discontinued for
obvious ethical and clinical considerations. Anti-cholin-estherases
(Gambi et al., 2004; Reale et al., 2004; Shearman et al., 2006; Calciano
et al., 2010), anti-psychotics (Chen et al., 2011a, 2011b), benzo-
diazepines and anti-depressants (Xia et al., 1996) are known to alter
serotonin-levels and various immune parameters, although these reports
are rather conﬂicting. As AD and LOD patients may generally use such
drugs, the observed ﬁndings might also be caused or inﬂuenced by their
ongoing treatments, however the only signiﬁcant and important ﬁnding
was with the 5-HT2C in NK-cells and not with any of the other
serotonin-receptor subtypes or PBMC sub-populations examined which
raises the possibility that the observed change is not clearly a drug-effect.
Despite these limitations, this study – to the best knowledge of the
authors – reports for the ﬁrst time about signiﬁcantly increased 5-HT2C
in AD, explicitly in NK-cells. The observed AD-speciﬁc neuro-
transmitter status of peripheral cells may serve as a potential biomarkerfor less invasive and early diagnostic purposes. These ﬁndings also sup-
port the existence of bi-directional communication that occurs between
the immune system and CNS, andmay also address the yet unexplained
viral theory of AD and the participation of the inﬂammatory system in
the patho-physiology of the disease.
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